▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #410 by analyst upside · 2026-09-28
ENTX
Entera Bio Ltd.
Healthcare · Market Cap $475M · P/E 0x
ANALYST PRICE TARGET
+255.2%
implied upside to consensus target
Current Price $2.75
Consensus Target $9.75
Bull Target $11.0
Bear Target $9.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $0.91
52-Week High $4.2
YTD Return +55.1%
FUNDAMENTALS
Market Cap $475M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.35
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.91
52-Week High $4.2
Current Price $2.75
Bear Target $9.0
Bull Target $11.0
● Now $2.75 ● Target $9.75
TRADING DATA
Avg Volume 1.8M
YTD Return +55.1%
Analyst Count 4
Consensus Buy
Upside to Target +255.2%
Last Updated 2026-09-28

ANALYST SUMMARY

Entera Bio Ltd. (ENTX) is currently trading at $2.75 with a Wall Street consensus price target of $9.75, implying potential upside of 255.2% over the next 12 months. 4 analysts currently cover ENTX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $9.0.

ENTX operates in the Healthcare sector with a market capitalisation of $475M. The stock is up 55.1% year-to-date and is currently trading near the upper end of its 52-week range of $0.91 – $4.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AGEN +208.4%
Agenus Inc.
$386M · P/E 2.8x · Buy
XFOR +285.4%
X4 Pharmaceuticals, Inc.
$298M · P/E 2.1x · Buy
SABS +253.7%
SAB Biotherapeutics, Inc.
$299M · P/E 13.7x · Buy
PLX +304.4%
Protalix BioTherapeutics, Inc.
$219M · P/E 11.8x · Buy
ZVRA +126.4%
Zevra Therapeutics, Inc.
$656M · P/E 11.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ENTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim ● Initiated
Buy 2026-09-25 62% win rate (8 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-09-22 40% win rate (10 calls)
Leerink Partners ● Initiated
Outperform 2026-09-18 29% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-04-27 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-02-09 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-18 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-11-11 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-10-07 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
12/30
Consensus clarity
15/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →